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CECR1-mediated cross talk between macrophages and
vascular mural cells promotes neovascularization in
malignant glioma
C Zhu1,2,6, I Chriﬁ3,6, D Mustafa1, M van der Weiden1, PJM Leenen4, DJ Duncker3, JM Kros1,7 and C Cheng3,5,7
Glioblastomas (glioblastoma multiforme, GBM) are most malignant brain tumors characterized by profound vascularization. The
activation of macrophages strongly contributes to tumor angiogenesis during GBM development. Previously, we showed that
extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) is highly expressed by M2-like
macrophages in GBM where it deﬁnes macrophage M2 polarization and contributes to tumor expansion. In this study, the effect of
CECR1 in macrophages on tumor angiogenesis was investigated. Immunohistochemical evaluation of GBM tissue samples showed
that the expression of CECR1 correlates with microvascular density in the tumors, conﬁrming data from the TCGA set. In a three-
dimensional co-culture system consisting of human pericytes, human umbilical vein endothelial cells and THP1-derived
macrophages, CECR1 knockdown by siRNA and CECR1 stimulation of macrophages inhibited and promoted new vessel formation,
respectively. Loss and gain of function studies demonstrated that PDGFB mRNA and protein levels in macrophages are modulated
by CECR1. The proangiogenic properties of CECR1 in macrophages were partially mediated via paracrine activation of pericytes by
PDGFB–PDGFRβ signaling. CECR1–PDGFB–PDGFRβ cross-activation between macrophages and pericytes promoted pericyte
migration, shown by transwell migration assay, and enhanced expression and deposition of periostin, a matrix component with
proangiogenic properties. CECR1 function in (M2-like) macrophages mediates cross talk between macrophages and pericytes in
GBM via paracrine PDGFB–PDGFRβ signaling, promoting pericyte recruitment and migration, and tumor angiogenesis. Therefore,
CECR1 offers a new portent target for anti-angiogenic therapy in GBM via immune modulation.
Oncogene advance online publication, 22 May 2017; doi:10.1038/onc.2017.145
INTRODUCTION
Glioblastoma multiforme (GBM) represents the highest grade of
glioma and carries a dismal prognosis of merely 12–15 months,
even after current standard chemo-radiotherapy and tumor
resection regimes.1 Presently, our understanding of the exact
mechanisms driving GBM pathogenesis remains limited and
further research is essential for the design of more effective
therapies. GBMs are highly vascularized tumors that are
hallmarked by vascular hyper-proliferative capacity2 and vast
myeloid inﬁltration.3
So far, the therapeutic effects of anti-angiogenic regimes
targeting VEGF were shown to be limited, due to rapid
acquirement of resistance by the tumor cells.4 It has been
proposed that the drug resistance may be related to the activation
of alternative angiogenic pathways such as FGF2-mediated and
HIF1-independent mechanisms that bypass the need for VEGFA
regulation of tumor angiogenesis.5 In addition, the recruitment
and activation of bone marrow-derived circulatory cells, including
macrophages, could rescue tumor angiogenesis by secretion of
these alternative proangiogenic factors.6
Previous studies have well established the involvement of
resident macrophages (microglia) and inﬁltrated macrophages,
also called glioma-associated macrophages (GAMs), in tumor
angiogenesis of GBM.7,8 Although GAMs can produce VEGFA,
alternative mechanisms including GAMs-induced RAGE-,9 CXCL210
- and IGFBP111-mediated regulation of tumor angiogenesis, have
also been demonstrated. In addition to regulating angiogenesis,
GAMs actively promote glioma growth, migration and invasion,12
and help maintain a glioma stem cell niche.13 Furthermore,
ﬁndings of clinical studies imply an important functional
contribution of GAMs to the prognosis or recurrence of
GBM.3,8,14,15 Several studies pointed out that macrophages in
GBMs mainly originated from major inﬁltrated myeloid cell
populations7,16,17 and not from resident microglia. A diminished
population of P2RY12+ cells (microglia cells) in GBMs was also
detected in our previous study.18 Macrophages are classically
distinguished into M1 and M2 phenotypes. M1 macrophages are
primarily associated with a pro-inﬂammatory state, whereas M2
macrophages are associated with immune modulation and wound
healing. Compared with M1 macrophages, M2 macrophages have
been shown to act proangiogenic, both in vitro and in vivo.19–21
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In line with these observations, recent studies have indicated that
mainly tumor-associated macrophages with a M2-like phenotype
can act as proangiogenic modulators, stimulating expansion of
disorganized neovessels by, for example, paracrine release of
PIGF22 and CCL18.23 In GBM, M2-like GAMs have been mainly
described for their immune-suppressive and tumor-supportive
function. As the majority of GAMs in GBM are known to have a
M2-like phenotype, speciﬁc drug targeting of M2 macrophages
could become a viable alternative therapy for the inhibition of
tumor angiogenesis in GBM.6
Recently, the extracellular adenosine deaminase protein Cat Eye
Syndrome Critical Region Protein 1 (CECR1) has been shown to
regulate macrophage maturation. In previous studies，we
demonstrated that CECR1 is consistently highly expressed by
M2-type GAMs, particularly in high-grade glioma.24 In line with the
ﬁndings presented by Navon et al.25 and Zhou and colleagues,26
we could validate that CECR1 is an important promoter of GAM
polarization towards M2-like macrophages. Our previous study
also demonstrated that CECR1-mediated paracrine activation of
M2-like GAMs directly affected the GBM cells, promoting tumor
cell proliferation and migration. However, the effect of CECR1
regulation of GAMs on tumor angiogenesis remains to be
investigated. Considering the important role that CECR1 has in
M2-like macrophage polarization, and the general proangiogenic
function of GAMs, we hypothesize that CECR1 contributes to the
paracrine proangiogenic function of (M2-like) GAMs.
In the present study, we demonstrated that CECR1 expression
correlated with microvascular density in GBM samples-based
analysis. Using a well-validated three-dimensional (3D) co-culture
system consisting of human pericytes, human umbilical vein
endothelial cells (HUVECs) and THP1-derived macrophages, we
further demonstrated that gain and loss of function of CECR1
activity in macrophages inhibited and promoted new vessel
formation, respectively. Further investigation revealed that CECR1
modulated pericyte function (mainly migration), a process that
was mediated by CECR1–PDGFB–PDGFRβ paracrine cross talk
between macrophages and pericytes.
RESULTS
CECR1 levels correlate with microvascular density in human GBM
Immunohistochemical analysis of human GBM samples indicated
strong CECR1 intensity in GBM samples with high microvascular
density, as shown by CD31+ staining of vascular endothelium
(Figure 1a). The high level of CECR1 coincided with a strong signal
of CD204+ M2 macrophages. In contrast, regions in GBM samples
with weak CECR1 immunostaining showed limited numbers of
CD204+ cells, and low microvascular density (Figure 1a). This
correlation between CECR1 and M2 macrophage markers (CD204,
in addition to CD163) was further validated in the TCGA database
(Supplementary Figure 1). Quantitative analysis using ImageJ
software conﬁrmed the data of this initial visual evaluation, with
the mean percentage of CD31+ area per image ﬁeld per GBM
sample being signiﬁcantly higher in the group of samples with
high versus low CECR1 levels (Figure 1b). Further analysis revealed
a signiﬁcant positive correlation between the CD31 and CECR1 in
the collection of GBM samples (Figure 1c). These data were in line
with the ﬁndings obtained by data mining in the TCGA data set:
signiﬁcant positive correlations were identiﬁed between PECAM1
(endothelial cell marker), Endoglin (endothelial (progenitor) cell
marker) and CECR1 expression in a set of 166 samples (Figures 1d
and f). The ﬁndings were validated in a second TCGA GBM set27 of
154 GBM samples (Figures 1e and g). Taken together, these
observations indicate that high CECR1 levels in GBM relate to
high microvascular density and the presence of CD204+ M2
macrophages.
CECR1 promotes the proangiogenic paracrine action of M2
macrophages
Previously, we have identiﬁed M2-like macrophages as the main
cell type in GBM to produce high levels of CECR1. We also showed
that CECR1 promotes M0 to M2 macrophage polarization and
determined M2 paracrine activity. Here we investigated the
function of CECR1 in macrophage-mediated angiogenesis in a
GBM-like environment. Angiogenesis was assessed in a 3D
co-culture assay consisting of a collagen matrix in which GFP-
labeled HUVECs directly interact with dsRed-labeled human-
derived pericytes. This complex system mimics the complete
sequence of events in microvasculature formation, allowing us to
study vessel sprouting, vascular cell migration through a 3D matrix
environment, multicellular vessel formation, lumenization, peri-
cyte recruitment, perivascular coverage and microvascular stabi-
lization, all within a 5-day time range. To assess CECR1 function in
GAMs in a GBM environment, THP1 monocytic cells were
maturated by stimulation with PMA for 48 h, before transfection
with CECR1 targeting siRNA to obtain CECR1-silenced macro-
phages. These siCECR1 macrophages were further stimulated for
48 h with or without U87-derived medium to assess the effect of a
GBM paracrine environment. To assess the paracrine effect of the
modiﬁed macrophages on angiogenesis, the THP1-derived
macrophages were harvested and seeded on top of the co-
culture system (Figure 2a). Stimulation of the co-cultures with
THP1 macrophages signiﬁcantly increased microvascular density,
as observed by quantitative analysis of the number of tubules,
total tubule length and number of junctions at day 5 (Figures 2b, c
and f). Successful siRNA-mediated knockdown CECR1 in THP1
macrophages, as validated by western blot and quantitative PCR
(qPCR, Figure 2e), signiﬁcantly reduced the response of the co-
culture to the macrophages, as shown by a reduction in total
tubule length compared with treatment with sisham and control
macrophages. These effects were further ampliﬁed when the co-
cultures were treated with THP1 macrophages stimulated with
U87 supernatant during maturation, with CECR1-silenced+U87
supernatant-treated THP1 cells reducing the number of tubules
and junctions and decreasing the total tubule length in the
exposed co-cultures compared with the control groups
(Figures 2d and f–h). In contrast, stimulation of co-cultures with
THP1 macrophages that were stimulated with human recombi-
nant CECR1 during maturation, showed a signiﬁcant increase in all
assessed vascular parameters (Supplementary Figures 2a and b),
demonstrating a dose–response relation. In addition, stimulation
with exogenous CECR1 during macrophage maturation induced a
partial rescue of attenuated tube formation that was triggered by
THP1 cells with CECR1 silencing (Supplementary Figure 3).
Our previous studies demonstrated that M2 macrophages were
the main producers of CECR1 in GBM. Here we investigated
whether the paracrine proangiogenic effects could be partially
mediated by direct stimulation of vascular cells by CECR1. Indeed,
stimulation of the co-cultures with recombinant CECR1 increased
the number of junctions, tubules and total tubule length,
demonstrating that vascular cells can be directly stimulated by
CECR1 (Supplementary Figures 4a and b). Combined, these data
indicate that CECR1 has an important role in regulating the
proangiogenic function of macrophages.
PDGFB expression correlates with M2 GAMs and is enhanced by
CECR1
To identify which particular known proangiogenic molecules are
associated to the expression of CECR1, qPCR was carried out on
nine well-recognized proangiogenic genes (PDGFB, VEGFA,
ANGPT1, ANGPT2, MMP7, MMP9, VWF, IL8, Tie-2). QPCR analysis
of macrophages showed that stimulation with recombinant
human (rh)CECR1 signiﬁcantly increased PDGFB in a dose-
responsive manner (Figure 3b, Supplementary Figure 5). In
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Figure 1. CECR1 levels correlates with microvascular density in human GBM. (a) Immunohistological staining of human GBM cross-sections for
CD31, CECR1 and CD204, in samples with high CECR1 signal (column High) and low CECR1 signal (column Low; scale bar:, 200 μm). (b) Results
of a quantitative analysis using ImageJ software of the mean percentage of CD31+ cells per image ﬁeld per GBM patient in CECR1 low- and
high-signal groups. (c) The correlation between mean %CD31+ cells and %CECR1+ cells per image ﬁeld per GBM patient. (d) Correlation
between PECAM1 and CECR1 mRNA levels in a set of 166 TCGA data set-derived GBM samples. (e) Correlation between PECAM1 and CECR1
mRNA levels in a second set of 154 TCGA data set-derived GBM samples. (f) Correlation between Endoglin and CECR1 mRNA levels in a set of
166 TCGA data set-derived GBM samples. (g) Correlation between Endoglin and CECR1 mRNA levels in a second set of 154 TCGA data set-
derived GBM samples. ***Po0.01.
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contrast, expression levels of other proangiogenic genes including
VEGFA were not affected (ANGPT1, ANGPT2, MMP7, MMP9, VWF,
Tie-2; Supplementary Figure 5), except for IL8. The latter is more
associated with the cytokine proﬁle of M1 macrophages. Vice
versa, macrophages of silenced CECR1 showed a signiﬁcant
decrease in expression of PDGFB (Figure 3a). These data were
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further validated by immunoﬂuorescent staining of cytospin THP1
macrophages, showing a reduction in PDGFB signal that coincided
with a reduction in CD163 (M2) marker signal in the CECR1-
silenced versus control macrophages and sisham-treated macro-
phages (Figure 3c). This effect was CECR1 knockdown speciﬁc, as
knockdown of PDGFB in THP1 macrophages did not reduce the
CD163 M2 marker signal, while the PDGFB signal was clearly
decreased (Figure 3c). In contrast, treatment of macrophages with
rhCECR1 increased both CD163 and PDGFB mean intensity signals
(Figure 3e). Quantiﬁcation of the mean intensity levels of PDGFB of
the different groups conﬁrmed that PDGFB was decreased and
increased by CECR1 silencing, and rhCECR1 stimulation, respec-
tively (Figure 3d). Stimulation of THP1 macrophages with U87-
derived supernatant promoted upregulation of PDGFB signal in
cytospin samples. This effect was signiﬁcantly reduced in siCECR1-
versus sisham-treated THP1 macrophages (Figures 3f and g).
A correlation between CECR1 and PDGFB levels was also found by
analysis of TCGA data sets, which showed a positive correlation
between PDGFB and CECR1 expression levels in a provisional set
of 166 GBM samples, and was subsequently validated in a second
set of 154 GBM samples (Figures 3h and i). Similar to CECR1,
immunostaining of GBM samples revealed that PDGFB+ cells were
mainly GAMs that express pan macrophage and M2 markers such
as CD68 and CD163 (Figure 3j).
CECR1-mediated paracrine activation of macrophages promotes
pericyte recruitment via PDGFB/PDGFRβ signaling in GBM
To assess the role of PDGFB in CECR1 regulation of macrophages
in angiogenesis, we conducted co-culture experiments with
macrophages silenced for PDGFB. Co-cultures with PDGFB-
silenced macrophages seeded on top mimicked the phenotype
of co-cultures that were treated by CECR1-silenced macrophages,
demonstrating a general decrease of all parameters of active
angiogenesis (Figures 4a–e). Co-culture analysis of siPDGFB
macrophages that differentiated with exposure to U87 super-
natant showed a similar negative effect on angiogenic parameters
(Supplementary Figures 6a and b). This reduction was partially
rescued by treating siPDGFB macrophages with rhCECR1 (siPDGFB
versus siPDGFB+rhCECR1, total tubule length), indicating that the
paracrine proangiogenic effect of CECR1 in macrophages is
partially mediated via PDGFB (Figures 4a–e). PDGFB mediates its
activity via PDGFB receptor (PDGFRβ) signaling. In GBM samples,
immunostaining revealed that PDGFRβ+ cells are mainly perivas-
cular mural cells that are closely located near CD163+ M2
macrophages (Figures 5a and b). QPCR analysis of different
in vitro human cell types that have equivalents in GBM in vivo,
including HUVECs, pericytes, U87, U251 and THP1 macrophages,
demonstrated that PDGFRβ was mainly expressed by pericytes
(Figure 5c). Confocal imaging combined with double immunos-
taining further conﬁrms mural cell expression of PDGFRβ and the
close localization of CD163+ GAMs in human GBMs (Figure 5d).
The PDGFB/PDGFRβ ligand/receptor signaling mechanism is well
known to promote mural cell proliferation and is critical for mural
cell recruitment to newly formed vessels to ensure vascular
coverage and stabilization. Next, we investigated the CECR1-
mediated effects of THP1 macrophages on pericyte recruitment.
Pericytes were evaluated for their migratory capacity in a transwell
migration assay in response to paracrine factors that are present in
macrophage-derived supernatants of the different groups
(Figure 5e). Pericyte migration increased on stimulation by
supernatant of THP1 macrophages (Figures 5f and g). Pericyte
migration signiﬁcantly decreased in response to supernatant
derived from CECR1-silenced THP1 macrophages (Figures 5e–g).
This effect was mimicked by exposure to supernatant derived
from PDGFB-silenced THP1 macrophages (Figures 5f and g).
To investigate whether direct binding of CECR1 to PDGFRβ
in pericytes may also regulate pericyte response, co-
immunoprecipitation (Co-IP) was conducted. Pull-down of
PDGFRβ protein using anti-PDGFRβ-coated beads in lysates of
CECR1-treated and non-treated pericytes was successfully vali-
dated. Likewise, pull-down of CECR1 using anti-CECR1-coated
beads was also successful. However, it failed to demonstrate
CECR1 binding to PDGFRβ protein in both conditions, indicating
that there is no direct contact of CECR1 with PDGFRβ in pericytes
(Supplementary Figure 7).
CECR1 activation in THP1 macrophages promotes paracrine
activation of periostin and VEGFA protein production in pericytes
Further confocal immunohistochemical analysis of human GBM
samples revealed co-localization of PDGFB+ perivascular mural cells
with the extracellular matrix component periostin (Figure 6a).
Previously, we have detected enrichment of periostin in the
microvasculature of GBMs using a proteomics screen.28 Work by
others revealed an important role for periostin in recruitment of M2-
like tumor-associated macrophages and subsequent support of
malignant growth.13 In line with these reports, periostin deposition
was detected in close proximity of CD163+ M2 GAMs (Figure 6b). A
signiﬁcant positive correlation was also identiﬁed between CD163
and periostin expression in a set of 154 samples using the TCGA
GBM database (Figure 6c). Similar to PDGFRβ, qPCR analysis of
different in vitro human cell types that can be found in GBM,
including HUVECs, pericytes, U87, U251 and macrophages, demon-
strated that periostin was mainly expressed by pericytes (Figure 6d).
Paracrine stimulation of pericytes by THP1 macrophages enhanced
periostin protein levels in the co-culture setup (Figures 6e and f).
THP1 macrophages stimulated with U87 supernatant during
maturation further enhanced periostin protein levels (Figures 6e
and f), indicating that GAMs can signiﬁcantly promote periostin
protein production in pericytes.
Periostin expression correlates (r= 0.3015; Po0.0001) with
CECR1 expression levels in a set of 205 samples derived from
the TCGA GBM database (Figure 6g). The periostin protein levels of
pericytes exposed to the paracrine activity of THP1 macrophages
dropped signiﬁcantly following silencing the macrophages for
Figure 2. CECR1 promotes the proangiogenic paracrine action of M2 macrophages. (a) Diagram showing the experimental setup of testing
paracrine angiogenic activation of vascular cells in 3D co-cultures by THP1 macrophages. (b) Low and high-magniﬁcation ﬂuorescent images
of neo-vessel formation by HUVECs (GFP-marked) and human-derived pericytes (dsRed-marked) without THP1 macrophage stimulation.
(c) Low- and high-magniﬁcation ﬂuorescent images of neo-vessel formation by HUVECs (GFP-marked) and human-derived pericytes (dsRed-
marked) with stimulation of non-treated (control), and sisham- or siCECR1-treated THP1 macrophages. (d) Low- and high-magniﬁcation
ﬂuorescent images of neo-vessel formation by HUVECs (GFP-marked) and human-derived pericytes (dsRed-marked) with stimulation of non-
treated (control), and sisham- or siCECR1-treated THP1 macrophages with U87 stimulation (scale bar, 100 μm for b–d). (e) Upper image:
western blot of CECR1 protein and β-actin loading control in THP1 macrophages. Blot represents results from three observations. Lower
graph: QPCR results of CECR1 mRNA levels normalized to housekeeping genes in non-treated (control), and sisham- or siCECR1-treated THP1
macrophages, without and with U87 stimulation. *Po0.05; **Po0.01. (f–h) Quantiﬁed results of the co-culture experiment. Number of
junctions, tubules and total tubule length data are shown. *Po0.05; **Po0.01. (MФ (-) versus MФ-control, U87 MФ-control versus
MФ-control, MФ-sisham versus MФ-siCECR1, U87 MФ-sisham versus U87 MФ-siCECR1). Representative graphs were taken from at least three
experiments. Six wells were analyzed in each experiment.
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CECR1 (Figures 6h and i). Silencing of PDGFB in the THP1
macrophages also resulted in decreased periostin production by
pericytes (Figures 6h and i). In support of these ﬁndings, THP1
macrophages that were treated with rhCECR1 during maturation,
increased periostin protein levels produced by pericytes
(Figure 6j). Similarly, periostin production by pericytes that were
directly stimulated with physiological levels of PDGFB was
signiﬁcantly increased (Figures 6k and l). Applying the same
experimental settings, CECR1 was found to regulate VEGFA
production in pericytes in a macrophage-dependent manner
(pericytes in response to CECR1 modulated macrophages) and
macrophage-independent manner (direct CECR1 and PDGFB
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stimulation of pericytes; Supplementary Figures 8 a–d). Direct
stimulation of pericytes with rhCECR1 did not enhance periostin
production, but it did enhance VEGFA production (Figure 6m,
Supplementary Figure 8c), indicating that the CECR1-mediated
macrophage activation of periostin expression in pericytes is
indirect and requires an intermediate paracrine factor, such as
Figure 3. PDGFΒ expression correlates with M2 GAMs and is enhanced by CECR1. (a) QPCR analysis of PDGFB mRNA levels normalized to
housekeeping genes in non-treated (control), and sisham- or siCECR1- or siPDGFΒ-treated THP1 macrophages. *Po0.05; ***Po0.005 versus
control and sham conditions. Experiments were repeated at least three times. (b) QPCR analysis of PDGFΒ mRNA levels normalized to
housekeeping genes in THP1 macrophages treated with different concentrations of rhCECR1 from three experiments. *Po0.05; ***Po0.005
versus no rhCECR1 stimulation. (c) Image panel shows immunoﬂuorescent staining of PDGFB and CD163, and merged images of cytospin
non-treated (control), and sisham- or siCECR1- or siPDGFB-treated THP1 macrophages (scale bar, 10 μm). (d) Graph shows mean PDGFB
intensity of each treatment group. **Po0.01; ***Po0.005 versus sisham condition. Experiments were repeated at least three times. (e) Image
panel shows immunoﬂuorescent staining of PDGFB and CD163, and merged images of cytospun non-treated (control), and rhCECR1-treated
THP1 macrophages (scale bar, 10 μm). Graph at the right shows mean PDGFB intensity of rhCECR1 stimulation versus no stimulation.
***Po0.005 versus no treatment condition. (f) Immunoﬂuorescent staining of PDGFB (green) and CD163 (red), and merged images of
cytospin non-treated controls with exposure to U87 supernatant U87 conditioned medium (CM), and THP1 macrophages treated with sisham
+U87 supernatant or siCECR1+U87 supernatant. (g) Mean PDGFB intensity of each treatment group from at least three experiments.
**Po0.01; ***Po0.005. (h) Correlation between PDGFB and CECR1 mRNA levels in a set of 166 TCGA data set-derived GBM samples.
(i) Correlation between PDGFB and CECR1 mRNA levels in a second set of 154 TCGA data set-derived GBM samples. (j) Low- and high-
magniﬁcation confocal images of double immunoﬂuorescent staining of CD68, CD163 and PDGFB, CECR1 in human GBM sections (scale bars,
50 μm (left panel); 5 μm (right upper panel), 10 μm (right lower panel)).
Figure 4. CECR1-mediated macrophage paracrine activation of angiogenesis is partially regulated via PDGFB. (a and b) Low- and high-
magniﬁcation ﬂuorescent images of neo-vessel formation by HUVECs (GFP-marked) and human-derived pericytes (dsRed-marked) without
THP1 macrophage stimulation, and with stimulation of non-treated (control), and sisham- or siPDGFB-treated THP1 macrophages, without or
with rhCECR1 rescue. (c–e) Quantiﬁed results of the co-culture experiment. Number of junctions, tubules and total tubule length data are
shown. *Po0.05 (MФ (-) versus MФ-control, MФ-sisham versus MФ-siPDGFB, MФ-sisham CECR1 0 nM versus 50 nM, MФ-siPDGFB CECR1 0 nM
versus CECR1 50 nM); **Po0.01 (MФ-sisham CECR1 0 nM versus 50 nM in number of tubules), ***Po0.005 (MФ-sisham CECR1 0 nM versus
50 nM in total tubule length). Scale bar, 100 μm. N410 co-cultures in total.
CECR1 regulates neovascularization in glioma
C Zhu et al
7
Oncogene (2017) 1 – 13
PDGFB. In line with these ﬁndings, direct stimulation of pericytes
with PDGFB promoted pericyte migration, and silencing of
periostin in pericytes (Figure 6n) inhibited this response
(Figures 6o and p).
Further evidence for the involvement of periostin in angiogen-
esis and cell migration is provided by correlation analysis of
periostin expression in three different TCGA-derived human GBM
data sets (Supplementary Figure 9a). Overlap analysis identiﬁed a
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set of 139 genes that was signiﬁcantly correlated with periostin
expression in the three GBM gene sets (Supplementary Figure 9b).
Functional annotation of the 139 genes identiﬁed the top 20 of
the signiﬁcant biological processes including angiogenesis-related
GO terms such as ‘blood vessel morphology’, ‘angiogenesis’,
‘blood vessel development’ and ‘cardiovascular system develop-
ment’ (Supplementary Figure 9c). GO terms associated with cell
migration such as ‘cell adhesion’, and ‘extracellular matrix
disassembly’ were also identiﬁed (Supplementary Figure 9c).
Taken together, the data reveal a link between periostin
expression by pericytes and CECR1-mediated macrophage para-
crine activity.
DISCUSSION
The main ﬁndings of this study are: (i) expression of CECR1 is
positively correlated with microvascular density in glioblastoma;
(ii) CECR1 expression by GAMs promotes angiogenesis in a 3D co-
culture assay; (iii) the level of CECR1 regulates PDGFB production
in GAMs; (iv) the CECR1–PDGFB-mediated cross talk between
macrophages and pericytes promotes migration of pericytes and
contributes to new vessel formation; (v) macrophage–pericyte
CECR1–PDGFB–PDGFRβ signaling upregulates the expression of
the proangiogenic extracellular matrix component periostin in
pericytes.
Current knowledge of the proangiogenic capacities of GAMs
mainly concerns the effects of these cells on vascular endothelial
cells.29 The regulation of perivascular cells, such as pericytes, by
GAMs, is rarely studied. In this study, we describe the proangio-
genic role of CECR1 that is mediated via an autocrine feedback
loop in which CECR1 production in M2-like GAMs enhances
PDGFB expression and secretion. Furthermore, CECR1 from M2-
like GAMs enhances VEGFA production in pericytes. PDGFB/
PDGFRβ signaling is crucial for the vascular maturation process in
angiogenesis, during which newly formed microvessels secrete
PDGFB to guide perivasular coverage by pericytes as well as
VEGFA production. PDGFB secreted by M2-like GAMs promotes
both pericyte migration and angiogenesis, as shown by our
migration and 3D co-culture data, respectively. Depletion of
PDGFB mimicked the vascular phenotype that was triggered by
depletion of its putative upstream molecule, CECR1.
Periostin is an extracellular matrix protein that is speciﬁcally
present in the basal membrane of the microvasculature of GBMs.19
In the present study, we identiﬁed periostin as a potent
downstream target of the macrophage CECR1–PDGFB paracrine
signaling cascade (see Supplementary Data Figure 10). Pericytes
are deﬁned by their singular perivascular position, their remark-
able dendrite-like morphology and their expression of PDGFRβ
and NG-2.30 Pericytes are multifunctional cells,31 being vital cells
for vessel construction, maintenance and the regulation of the
vascular physiology.32 Pericyte dysfunction could lead to delay in
blood vessel maturation, and contributes to vascular instability
and leakage.33 Pericytes also contribute to recruitment of immune
cells, including monocytes, during inﬂammation.34 A process of
mutual activation between GAMs and pericytes during tumor
angiogenesis has been previously identiﬁed. In tumors, the
paracrine inﬂuence of GAMs leads to activation of the PDGFB–
SOX17 axis, which is initiated by tumor cells and leads to pericyte
production of IL-33.35 In addition, tumor-associated macrophages
secrete MMP9, which has been shown to enhance the recruitment
of pericyte precursor cells into the tumor microenvironment.36 The
present data demonstrate the proangiogenic function of CECR1 in
macrophages, mediated via paracrine regulation of PDGFB. The
relation between CECR1, angiogenesis and vascular density is
reﬂected by the hyper-inﬂammatory response in patients with a
CECR1 loss of function mutation.26 One of the most prominent
symptoms displayed by these patients was early-onset stroke and
profound vasculopathy. Similarly, vascular instability was observed
in zebraﬁsh with CECR1 knockdown. In previous studies, we
pointed out that CECR1 in GBM is mainly expressed by M2-like
GAMs. We also discovered that CECR1 acts as a potent polarizing
factor in GAMs differentiation towards the M2-like phenotype.
CECR1 activity also increased the pro-tumoral function of M2
macrophages in a paracrine manner.37 In the current study, we
have shown that CECR1 activity in GAMs enhances PDGFB mRNA
and protein production levels. In line with these ﬁndings, PDGFB
was previously reported not only to be expressed by activated
endothelial cells, but also by M2-like GAMs.38 Elevated levels of
PDGFB produced in malignant cancers upregulate erythropoietin
expression in stromal cells via activation of PDGRB that accelerates
tumor angiogenesis.39 The CECR1–PDGFB–PDGFRβ axis that is
revealed in this study points to a putative CECR1-mediated
functional cross talk between macrophages and pericytes, guiding
the process of vascular maturation and development. This process
may be involved in the vascular symptoms observed in patients
with CECR1 mutations.25 However, it has to be acknowledged that
the qPCR screen only included a limited selection of cytokines that
were known to affect angiogenesis and were reportedly produced
by macrophages. Future studies should aim on expanding the
current screen data using a genome-wide approach to identify
additional (secreted) factors that may be regulated by CECR1
in GAMs.
Aberrant vessel morphology with abnormal pericyte coverage is
considered as one of the classical hallmarks of tumor vasculature
in malignant tumors including GBM. Recent studies of pericytes
have revealed hyperplasia of this cell type in GBM.40 The function
of pericytes in malignant tumors is not only restricted to support
vascular growth, but as a potent producer of VEGFA, perivascular
pericytes also protect the tumor microvasculature against disin-
tegration during anti-VEGFA therapy by elevating local VEGFA
levels.31 Furthermore, pericytes in glioma were shown to produce
other angiogenic molecules like HGF, TGFβ1 and prostaglandins.
Pericytes also inhibit the activation of T cells and thereby induce
immunosuppression in glioma,41 while expressing plasminogen
urokinase in support of the self-renewal and invasion of glioma
initiating cells.42 Based on these reports, we can conclude that
Figure 5. CECR1-mediated paracrine activation of macrophages may promote pericyte recruitment via PDGFB/PDGFRβ signaling in GBM.
(a) Low (right panel) and high (left panel) immunohistological staining of PDGFRβ and CD163 in human GBM sections. Black arrows indicate
pericytes and endothelial cells (EC) forming blood vessels (BV). White arrow indicates macrophages (Mφ) (Scale bar, 200 μm (left panel); 40 μm
(right panel)). (b) High-magniﬁcation image of PDGFRβ immunohistological staining in human GBM sections. (c) QPCR analysis of PDGFRβ
mRNA expression levels normalized to housekeeping genes in HUVECs, pericytes, U87, U251 and THP1 macrophages from three experiments.
***Po0.001 (pericytes versus other cell types). (d) Confocal images of CD163 and PDGFRβ double immunoﬂuorescent staining in human GBM
sections. White arrows indicate pericytes, endothelial cells (EC) and macrophages (Mφ). Scale bars, 50 μm (left panel); 20 μm (right panel).
(e) Diagram of the experimental setup of the transwell migration assay of pericytes (dsRed-marked) seeded on top of the transwell. Cell
migration was towards a lower chamber with DMEM medium only, or with supernatant derived from non-treated (control) macrophages, and
sisham- or siCECR1-treated macrophages. (f) Panel of ﬂuorescent images of dsRed-marked pericytes that have migrated through the transwell
setting in response to the different conditions (DMEM only, or in response to supernatant of non-treated macrophages (control), or sisham-,
siCECR1- or siPDGFRβ-treated macrophages). (g) Quantiﬁed results of the transwell migration assay. **Po0.01 (MΦ(-) versus Control);
***Po0.005 (sisham versus siCECR1; sisham versus siPDGFB), N46 migration assays per condition.
CECR1 regulates neovascularization in glioma
C Zhu et al
9
Oncogene (2017) 1 – 13
pericytes have multiple signiﬁcant roles in promoting angiogen-
esis and tumor progression in glial tumors.
In this study, we have identiﬁed periostin as a downstream
target of PDGFB signaling in pericytes. Periostin was identiﬁed as a
proangiogenic extracellular matrix component in glioma.28 As a
multifunctional protein, it is involved in various carcinogenic
processes such as the regulation of cell migration and the
epithelial–mesenchymal transition in cancer cells, mainly via
activation of cell focal adhesion kinases through cell binding to
integrins.43 Recently, periostin was shown to have a role in the
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recruitment of M2-like GAMs in GBM13 and to mediate the
resistance to anti-VEGFA therapy by increasing expression of
caveolin-1, HIF-1α and VEGFA.44 In addition, periostin is expressed
by mammary stromal cells in breast cancer where it is involved in
actively maintaining a breast cancer stem cell niche via the
canonical WNT signaling pathway.45 In pancreatic carcinoma, the
expression of periostin was found upregulated in response to
PDGFB stimulation.46 Our data provide evidence that the
modulation of CECR1 in macrophages inﬂuences the expression
of periostin in pericytes via PDGFB-mediated paracrine signaling.
In conclusion, this study demonstrates that in glioblastoma
CECR1 produced by M2-like GAMs regulates the cross talk
between macrophages and pericytes via paracrine PDGFB–
PDGFRβ signaling, promoting pericyte recruitment and migration,
and tumor angiogenesis. The proangiogenic function of
the CECR1–PDGFB–PDGFRβ signaling cascade is related to the
expression of periostin by pericytes. This new knowledge on
complex interaction between the immuno apparatus and vascular
cells in the process of tumor neo-angiogenesis could lead to
better immune-modulatory and anti-angiogenic strategies for the
treatment of GBM in the future.
MATERIALS AND METHODS
Patient samples
Patient samples of glioblastoma were collected from the Department of
Pathology, Erasmus Medical Center with the approval of committee of
research ethics and all the subjects. All the samples were diagnosed as
glioblastoma by a board certiﬁcated pathologist (JMK).
Cell culture
Human monocytic cell line THP1 (authenticated and tested mycoplasma
free), obtained from the Department of Hematology, Erasmus Medical
Center, was maintained in culture in RPMI-1640 (Lonza, Breda, The
Netherlands) supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin. THP1 cells were differentiated into macrophage-
like cells by PMA (Sigma, Stockholm, Sweden) at a concentration of
100 ng/ml for 48 h. Recombinant human CECR1 protein (rhCECR1) was
added to the macrophage cultures at a concentration gradient of 0, 12.5,
25, 50, 100, 200 nM for 96 h.
HUVECs (Lonza) and HUVECs transfected with a lentiviral vector
encoding GFP were cultured in EGM-2 endothelial medium (Lonza) with
1% penicillin/streptomycin.
Human brain vascular pericytes with and without lentiviral transfection
of a vector encoding for dsRed, and GBM cell lines U87 and U251,
purchased from ATCC, were maintained in DMEM (Lonza) with 10% fetal
bovine serum and 1% penicillin/streptomycin. Pericytes were treated with
recombinant human PDGFΒ (Sigma) at different concentrations according
to the speciﬁcations of the different assays. All cultured cells were checked
to be negative for mycoplasma contamination. HUVECs and pericytes were





GCACCGGAAAUUCAA-3′, 5′-GGGCCGAGUUGGACCUGAA-3′), siPOSTN (5′-CCG
AAGCUCUUAUGAAGUA-3′) and scrambled siRNA (5′-UGGUUUACAUGUCGAC
UAA-3′, 5′-UGGUUUACAUGUUGUGUGA-3′, 5′-UGGUUUACAUGUUUUCUGA-3′,
5′-UGGUUUACAUGUUUUCCUA-3′) (siSham) were purchased from Dharmacon
(GE Health Care, Lafayette, LA, USA). Macrophages were transfected with
SiCECR1 and siPDGFΒ using transfection buffer 2 (Dharmacon, GE Health Care);
pericytes or pericytes-dsRed were transfected with siPOSTN using transfection
buffer 1 (Dharmacon, GE Health Care) according to manufacturer's instructions
(see Supplementary Materials and Methods for details).
RNA isolation and RT-qPCR
Total RNA was isolated from macrophages and pericytes using RNA
isolation kit (Bioline, London, UK) and cDNA was synthesized by sensi-fast
cDNA synthesis kit (Bioline). Transcripts of CECR1, PDGFΒ and POSTN were
measured and normalized to β-actin in macrophages and pericytes (for
primers sequences, see Supplementary Table 1).
Transwell co-culture
Macrophages were seeded in 0.4 μm transwell insert (Fisher Scientiﬁc,
Denver, CO, USA) and were treated with U87-derived conditioned medium
or recombinant human (rh)CECR1 protein for 48 h followed by co-culture
with pericytes for extra 72 h. The pericytes were collected afterwards for
performing downstream assays.
Co-immunoprecipitation
Pericytes cultured in serum-free DMEM medium were treated with/without
100 nM CECR1 for 6 h. The cells were collected in NP40 lysis buffer followed
by incubation on ice for 30 min and were centrifuged for 12 min at
13 000 r.p.m. The supernatant was collected for co-immunoprecipitation.
The 1.5 mg Dynabeads (Life Technologies, Bleiswijk, The Netherlands) were
incubated with anti-PDGFRβ (CST, Leiden, The Netherlands) antibody or
Isotype control from the same host (CST) for 10 min at room temperature
followed by gently washing using the provided washing buffer and
magnet separation (Life Technologies). A total 100 μg of lysate was added
to the Dynabeads–antibody complex and incubated for 48 h at 4 °C. The
formed Dynabeads–antibody–antigen complex was washed followed by
elution of the target antigen at 70 °C for 10 min in provided elution buffer
Figure 6. CECR1 activation in THP1 macrophages promotes paracrine activation of periostin protein production in pericytes. (a and b)
Confocal images of imunohistological stainings of periostin, PDGFRβ and CD163 in human GBM sections. Scale bar, 50 μm. (c) Correlation
between CD163 and periostin mRNA levels in a set of 154 TCGA data set-derived GBM samples. (d) QPCR analysis of periostin mRNA
expression levels normalized to housekeeping genes in HUVECs, pericytes, U87, U251 and THP1 macrophages from three experiments.
***Po0.001 (pericytes versus other cell types). (e) Diagram showing experimental setup with pericytes (green) co-cultured with macrophages
without (light blue) and with U87 pre-stimulation (dark blue) seeded in ﬁlter insert. Western blot shows periostin and β-actin protein levels in
pericytes of the different treatment groups. (f) Quantitative results of western blot analysis normalized to β-actin loading control from four
experiments. *Po0.05; ***Po0.005. (g) Correlation between periostin and CECR1 mRNA levels in a set of 205 TCGA data set-derived GBM
samples. (h) Western blot shows periostin and β-actin protein levels in pericytes treated with no macrophages, with non-transfected
macrophages (control), and macrophages transfected with sisham, siCECR1 or siPDGFRβ. (i) Quantitative results of western blot analysis
normalized to β-actin loading control from four experiments. *Po0.05. (j) Western blot shows periostin and β-actin protein levels in pericytes
treated with macrophages with and without pre-treatment with rhCECR1. Graph shows quantitative results of western blot analysis
normalized to β-actin loading control of at least four experiments. *Po0.05 versus no rhCECR1 stimulation. (k) Western blot shows periostin
and β-actin protein levels in pericytes treated with different concentrations of PDGFB. (l) Quantitative results of western blot analysis
normalized to β-actin loading control from at least three experiments. **Po0.01; ***Po0.005 versus no PDGFB stimulation.
(m) Representative western blot of three independent experiments, showing periostin and β-actin protein levels in pericytes treated with
rhCECR1. (n) Western blot of periostin protein and β-actin loading control in pericytes with siPOSTN treatment, sisham or no treatment blot
represents results from three observations. (o) Panel of ﬂuorescent images of dsRed-marked pericytes that have migrated through the
transwell setting in response to the different conditions (in response to supernatant of non-treated macrophages (control), or sisham- or
siperiostin-treated macrophages), with and without PDGFB stimulation (scale bar, 50 μm). (p) Quantiﬁed results of the transwell migration
assay from three experiments. **Po0.01 (siPOSTN versus PDGFB+siPOSTN); ***Po0.005 (sisham versus siPOSTN; control versus PDGFB
+control; sisham versus PDGFB+sisham).
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with SDS loading buffer, followed by SDS–PAGE and western blotting.
Whole lysates and the supernatants of the Dynabeads–antibody–antigen
complex of every condition were loaded on the gel as internal controls.
Western blot
A total 20 μg of total protein lysate derived from macrophages and
pericytes was loaded onto 10% SDS–PAGE gel and blotted to Nitro
cellulous membranes followed by blocking and incubation of primary
antibody. Protein levels were assessed by immunoblotting using speciﬁc
antibodies against CECR1 (Sigma, 1:200), Periostin (R&D, Minneapolis, MN,
USA, 1:200), PDGFRβ (Abcam, Milton, UK, 1:10000), and β-actin (Abcam,
1:500) as a loading control, followed by incubation with secondary
antibodies (IRdye 680 CW, IRDye 800 CW, Licor Bioscience, Lincoln, NE,
USA) and detection of signals using the Odyssey imaging system (Licor
Bioscience).
Immunostaining
Four micrometers of adjacent sections were used for immunohistochem-
ical and immunoﬂuorescence analysis. Immunostaining and slide scanning
were performed according to the protocol described previously.47
Macrophages were ﬁxed using 4% paraformaldehyde/phosphate-buffered
saline, followed by antibody incubation. All ﬂuorescence-labeled samples
were analyzed under the confocal microscope LSM 700 (Zeiss, Breda, The
Netherlands). Five areas in high-magniﬁcation ﬁeld were randomly
selected from each slide and blind quantiﬁed using ImageJ (Antibodies
applied were listed in Supplementary Table 2).
Transwell migration assay
A total 7000 pericytes-dsRed with transfected with siPOSTN, siSham and
non-transfected controls were seeded into the top compartment of the
Fluor block 8 μm transwell inserts (Fisher Scientiﬁc). Recombinant PDGFΒ
protein was added in the lower chamber with serum-free DMEM medium.
Serum-free macrophage-conditioned medium from sisham, siCECR1,
siPDGFΒ and non-transfected control macrophages was added into the
lower chamber. After 24 h of migration, the pictures from ﬁve randomly
selected areas under × 10 view were taken under a ﬂuorescent microscope
for image quantiﬁcation by ImageJ.
3D collagen tubule-formation assay
HUVEC-GFP and pericyte-dsRed were co-cultured in 96-well plate at 5:1
ratio within a 3D culture environment of bovine collagen type I (Gibco,
Gaithersburg, MD, USA) supplemented with SCF-1, SDF-1α and IL-3, as
described previously.48 Three hundred macrophages with different
conditions were seeded on top of the collagen gel and maintained for
5 days. At the ﬁfth day, tubule formation was captured by ﬂuorescent
microscope and blind quantiﬁed by Angiosys 1.0.
TCGA database
Three GBM data sets were obtained from TCGA via the c-Bioportal
provided by the Memorial Sloan Kettering Cancer Center. Genes that
positively correlated with POSTN expression (cutoff point: spearman
r40.4) in all three GBM database were selected for pathway analysis by
String.
Statistics
Data from clinical samples were analyzed by Mann–Whitney U-test and
Spearman Correlation using SPSS 21.0 (IBM, Chicago, IL, USA). All in vitro
data were tested using unpaired two-tailed Student’s T-test or by one-way
analysis of variance followed by Tukey’s post hoc test where appropriate
(Signiﬁcance levels Po0.05). All data are presented in mean± s.e.m. unless
otherwise stated.
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